Clinical Trials Logo

Filter by:
NCT ID: NCT00255593 Completed - Clinical trials for Renal Transplantation

Safety and Efficacy Study of Rituximab in Renal Transplantation

Start date: November 2005
Phase: Phase 1
Study type: Interventional

Current strategies for the medical management of transplant patients are largely focused on the prevention and treatment of T-lymphocyte mediated processes. However there is an increasing evidence to suggest that B-lymphocytes have a role in the otherwise classic T-cell mediated rejection of transplants by there ability to act as antigen presenting cells and T-cell activators. Thus there is a significant medical need for effective therapies targeting B cells of transplant patients.One such potential therapy would be to use rituximab, a monoclonal antibody against B-cells in all renal transplant patients. In the present study the efficacy and safety of prophylactic rituximab is studied.

NCT ID: NCT00255515 Completed - Schizophrenia Clinical Trials

Seroquel® Combined With Cognitive Remediation Therapy to Conventional Treatment in Patients With Schizophrenia

SCORE
Start date: September 2005
Phase: Phase 4
Study type: Interventional

The purpose of this study is to compare efficacy of quetiapine fumarate combined with Cognitive Remediation Therapy (CRT) to conventional treatment by evaluating change in social outcome in patients with schizophrenia.

NCT ID: NCT00255463 Completed - Breast Cancer Clinical Trials

Phase II Neoadjuvant ER+/PgR + Arimidex +/- Iressa Study

Start date: January 2004
Phase: Phase 2
Study type: Interventional

The purpose of this study is to compare the changes in a proliferation biomarker in subjects receiving Anastrozole or Anastrozole/ZD1839 combination.

NCT ID: NCT00255281 Completed - Atrial Fibrillation Clinical Trials

Efficacy and Safety of AZD7009 in the Treatment of Atrial Fibrillation

Start date: September 2005
Phase: Phase 2
Study type: Interventional

The current study is designed to assess the efficacy and safety of iv AZD7009 in conversion from AF

NCT ID: NCT00252005 Completed - Clinical trials for Deep-Vein Thrombosis

Oral Direct Factor Xa-inhibitor Apixaban in Patients With Acute Symptomatic Deep-vein Thrombosis-The Botticelli DVT Study

Start date: November 2005
Phase: Phase 2
Study type: Interventional

The purpose of this clinical research study is to assess efficacy and safety of 3 doses of apixaban 5 mg twice a day, 10 mg twice a day and 20 mg once daily versus conventional treatment with low molecular weight heparin or fondaparinux and vitamin K antagonist in the treatment of subjects with acute symptomatic deep-vein thrombosis.

NCT ID: NCT00251992 Completed - Dyspepsia Clinical Trials

Nexium Dyspepsia/AST

Start date: December 2002
Phase: Phase 3
Study type: Interventional

The aim is to evaluate if the resolution of upper abdominal symptoms (pain or burning) during an acid suppressive test trial of esomprazole given daily for 7 days predicts symptoms resolution at the end of a subsequent treatment period of 7 weeks.

NCT ID: NCT00251979 Completed - Clinical trials for Gastrointestinal Hemorrhage

A Study to Prevent Rebleeding After Initial Successful Primary Endoscopic Haemostasis of a Bleeding Peptic Ulcer

Start date: October 2005
Phase: Phase 3
Study type: Interventional

This study is being carried out to see if constant 3 days infusion of Nexium is effective in preventing rebleeding after an endoscopic treatment.

NCT ID: NCT00251927 Completed - Clinical trials for Gastroesophageal Reflux

Esomeprazole (NEXIUM) vs. Surgery

LOTUS
Start date: October 2001
Phase: Phase 3
Study type: Interventional

The study investigates the efficacy of long-term treatment of esomeprazole compared to anti-reflux surgery in the control of gastroesophageal reflux disease by assessing time to treatment failure.

NCT ID: NCT00251914 Completed - Dyspepsia Clinical Trials

Nexium Dyspepsia/AST

Start date: December 2002
Phase: Phase 3
Study type: Interventional

The aim is to evaluate if the resolution of upper abdominal symptoms (pain or burning) during an acid suppressive test trial of esomprazole given daily for 7 days predicts symptoms resolution at the end of a subsequent treatment period of 7 weeks.

NCT ID: NCT00251901 Completed - Chest Pain Clinical Trials

Chest Pain Pilot Study

Start date: May 2004
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the efficacy of Nexium® with placebo in relief of acid related pain or discomfort in the chest.